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Edited by Varda RotterAbstract Axotrophin (axot) is a newly characterised stem cell
gene and mice that lack axotrophin are viable and fertile, but
show premature neural degeneration and defective development
of the corpus callosum. By comparing axot+/+, axot+/ and
axot/ littermates, we now show that axotrophin is also in-
volved in immune regulation. Both T cell proliferation and T
cell-derived leukaemia inhibitory factor (LIF) were suppressed
by axotrophin in a gene-dose-dependent manner. Moreover, a
role for axotrophin in the feedback regulation of LIF is impli-
cated. This is the ﬁrst evidence that fate determination mediated
by LIF maybe qualiﬁed by axotrophin.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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regulation1. Introduction
The immune response is subject to fate determination sig-
nals that ensure protective tolerance towards self tissues
whilst simultaneously being capable of aggressive attack to-
wards foreign pathogens. Speciﬁcity of a given response is
driven by antigen, whilst the phenotypic fate of the respond-
ing lymphocyte is guided by micro-environmental cues to re-
sult in either aggression, or tolerance. In self-tolerance,
CD4+CD25+ regulatory T lymphocytes arise within the thy-
mus and protect against auto-immunity in a forkhead tran-
scription factor P3 (Foxp3)-dependent manner [1]. Mouse
allograft models have shown that peripheral, naive CD4+
lymphocytes may also be guided towards regulatory toler-
ance by therapeutic manipulation of signal transduction
pathways at the time of initial antigen engagement [2–4].
Once established, a self-sustaining state of donor-speciﬁc tol-
erance occurs: this requires continuous presence of donorAbbreviations: FoxP3, forkhead transcription factor P3; STAT3, signal
transucer and regulator of transcription 3; SOCS3, suppressor of
cytokine signalling 3; IL, interleukin
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fully immune competent recipients of a donor-type graft
via ‘‘tolerant’’ lymphocytes [2]. Ex vivo analyses of tolerant
splenocytes revealed leukaemia inhibitory factor (LIF) re-
lease in response to donor antigen [5]. LIF is a key neuro-
poietic cytokine [6] and regulator of stem cells [7].
Comparative gene array of graft-‘‘tolerant’’ spleen cells ver-
sus graft-‘‘rejected’’ splenocytes identiﬁed axotrophin, a new-
ly characterised stem cell gene [9], as being speciﬁcally
increased in tolerance [8]. Here, we ask if axotrophin plays
a role in immune regulation and show not only that axotro-
phin plays a critical role in the regulation of T lymphocytes,
but also that axotrophin is functionally linked to the regula-
tion of LIF.2. Materials and methods
2.1. Axot null mice
The axotrophin gene was identiﬁed in an in vitro preselection gene
trap screen for novel genes involved in neural diﬀerentiation from
embryonic stem (ES) cells [6] and the detailed methods for preparation
of axot null mice are to be published elsewhere. Brieﬂy, ROSA beta-
geo [10] was inserted into the ﬁrst intron of axot creating a null allele.
ES cells heterozygous for the axot gene trap were injected into mouse
blastocysts to create transgenic animals on a BALB/c background. In
the experiments reported here, spleen, thymus and lymph node were
obtained from 5 month old littermates of axot null, heterozygous,
and wild type littermates and kept on ice prior to cell preparation
for the phenotypic and functional analyses described below. The
lymph node tissue yielded very few cells and was discarded. Spleen,
thymus, kidney and lung from littermates of each axot genotype were
also taken for histology.2.2. FACS analyses
Splenic and thymic cell suspensions were depleted of erythrocytes
and washed in FACS staining solution (0.2% BSA and 0.1% sodium
azide in 1· PBS) prior to being mixed with the various monoclonal
antibodies detailed below, these being either directly or indirectly
conjugated with phycoerythrin (PE) or ﬂuorescein isothiocyanate
(FITC). PE-rat anti-mouse CD19 (557399), PE-hamster anti-mouse
TCRa chain (553172) and rat anti-mouse dendritic cell clone
33D1 (551776) were from Pharmingen. Rat anti-mouse CD205-
FITC (MCA949F), mouse anti-rat IgG2a heavy chain-FITC
(MCA278F) and mouse anti-rat IgG2b chain-FITC were from Sero-
tec Ltd., while rabbit anti-mouse CD25 (IL2Ra) and goat anti-rab-
bit IgG (H&L)-PE (4050–89) were from Santa Cruz Biotechnology
and Southern Biotechnology Associates, respectively. Anti-CD4
(YTS177.9.6) and anti-CD8 (YTS 105.18.10) were a gift from Dr.blished by Elsevier B.V. All rights reserved.
610 S.M. Metcalfe et al. / FEBS Letters 579 (2005) 609–614Stephen Cobbold, University of Oxford. Analyses were performed
on a Becton Dickinson FACSCalibur instrument equipped with
CellQuest software.
2.3. Proliferation assays
Splenocytes and thymocytes were collected in sterile growth med-
ium, RPMI-1640 (Gibco Invitrogen Co.) supplemented with 10%
FCS. Cultures of 100 ll containing 5 · 105 nucleated cells per well were
incubated at 37 C, 5% CO2 for 48 or 72 h LPS (Sigma Chemical Co.)
at 50 lg/mL and conA (ICN Biochemicals, USA) at 10 lg/ml unless
otherwise indicated. All experiments were performed in triplicate and
are expressed as a mean: there was less than 10% variation in all cases.
Immediately prior to harvest, supernatants were collected for ELISA
analysis and the cells were labelled for 2 h with methyl-[3H]thymidine
(TRK686, speciﬁc activity 80 Ci/mmol, Amersham Biosciences) at a ﬁ-Fig. 1. Axotrophin null mice show normal spleen, thymic, kidney and lung d
and D) comparing axot null mice (/) with wild type (+/+). Kidney (E annal concentration of 1 lCi/mL. To determine the eﬀect of LIF on
conA-stimulated proliferation, BALB/c axot+/+ splenic and thymic
cells were incubated in the presence of conA (2 or 10 lg/mL) with or
without 500 pg/mL, or 1000 pg/mL, rmLIF (Santa Cruz Biotechnol-
ogy, SC-4378). To measure the relationship between LIF release and
T cell proliferation in axot+/+ spleen cells, a range of conA concentra-
tions were used to stimulate diﬀerent levels of proliferation.
2.4. Cytokine release
ELISA assays were performed on culture supernatants using the
DuoSet ELISA for IFNc (DY485), IL2 (DY402), IL4 (DY404),
IL10 (DY417) and Quantikine M Immunoassay for LIF (MLF00),
from R&D Systems. Goodness of ﬁt was measured for the standard
curves: this approached 1.0 in all assays. Sample replicates showed
high reproducibility.evelopment. H&E stained sections of spleen (A and B) and thymus (C
d F) and lung (G and H).
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3.1. Axotrophin expression
The axot gene sequence has been submitted to GenBank
(Accession No. AF155739) and details of expression are to
be described in full elsewhere (Haendel and Lyons, unpub-Fig. 2. Axot+/+ and axot/ mouse littermates show similar splenocyte and t
axot+/+ and axot/ spleen (A), and thymic (B), cells: cut-oﬀ for negative stai
double stained for CD4 and CD25, CD4 being on the axis, and CD25 the alished data). In summary, there is 87% identity and 91%
homology between mouse and human axotrophin; mouse axot
is localised within chromosome 2, band C1; and mouse axotro-
phin mRNA is highly expressed in most tissues upto E15.5,
thereafter being expressed at the highest levels in the nervous
system. Northern blot of axotrophin mRNA in adult tissueshymocyte phenotypic proﬁles. FACs analyses of whole populations of
ning indicated by the vertical line. Thymocytes (C) and splenocytes (D)
bscissa.
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ney, but little in spleen or liver. The incidence of axot/,
axot+/ and axot+/+ littermates derived from axot+/ parents
shows normal Mendelian ratios, indicating normal implanta-
tion and embryonic development of the null phenotype.
Although the null phenotype is very mild, neural defects occur,
these being agenesis of the corpus callosum during develop-
ment and degeneration of substantia gelatinosa lamina II ax-
ons in adulthood.
3.2. The axot null mouse has a normal lymphoid proﬁle
The spleen and thymus of 5 month old adult axot null mice
showed no overt structural abnormalities (Fig. 1, panels A–D)
nor were abnormalities of the kidney or lung tissues found
(Fig. 1, panels E–H). Thus, although axotrophin mRNA is
normally expressed in the adult thymus and kidney, axot is
not required for their development and maintenance. No lym-
phocytic inﬁltrate was found in the lung or glomerular region
of the kidney, known sites of auto-immune pathology [11],
suggesting that absence of axotrophin does not correlate with
aggressive immune self-reactivity, at least not after 5 months
maintenance in clean conditions. Comparing axot+/+ with
axot/ splenocytes (Fig. 2A) and thymocytes (Fig. 2B) by
FACS analyses of CD3, CD4, CD8, CD19, CD25 and 33D1
expression, and of cells co-expressing CD4 and CD25 (Fig.Fig. 3. Axot null splenocytes hyperproliferate and show dysregulation of LIF
for 48 h (upper panels) or 72 h (lower panels) with conA (left-hand panels
300 cpm. Supernatants from the 48 h cultures were assayed for cytokine rele
conA (left panels) or LPS (right panels).2C and D), no diﬀerences were found. We concluded that
development of T and B lymphocytes, and the incidence of
CD4+CD25+ T cells, was unaﬀected by lack of axotrophin.
3.3. Hyper-proliferation of axotrophin-null T cells
When we tested the responses of spleen cells to the T lympho-
cyte mitogen concanavalin A (ConA), or the B lymphocyte
mitogen, lipopolysaccharide (LPS), axotrophin-related diﬀer-
ences became apparent. Although both mitogens induced blas-
togenesis, there was a marked gene dose-dependent eﬀect of
axot on T cell progression to S phase of the cell cycle, this
increasing as axot gene dose decreased (Fig. 3A, left-hand pan-
els). Similar axotrophin-related diﬀerentials in proliferation oc-
curred at both 48 and 72 h, excluding the possibility that altered
response kinetics had led to the observed hyper-proliferation at
48 h. An alternative explanation for the measured hyper-prolif-
eration was that lack of axotrophin results in an increased rate
of cell division: this was discounted since the ﬁrst S phase peak
of ConA-activated T cells occurs at 48 h [12].We concluded that
lack of axotrophin resulted in a greater proportion of the T cell
population entering the cell cycle in response to conA, and that
axotrophin normally represses this proliferative response in a
gene-dose-dependent manner. In contrast to conA activation,
axotrophin had minimal eﬀects on B cell proliferation when
equivalent aliquots of the same spleen cell populations wererelease. (A) H3-thymidine uptake into DNA of spleen cells stimulated
) or LPS (right-hand panels). Background controls were all less than
ase: (B) levels of IL2 and IL10, (C) INFc and IL4, and (D) LIF, after
Table 1
Exogenous LIF does not stimulate proliferation from axot+/+ spleno-
cytesa
DNA synthesis at 48 h (stimulation index)
Treatment 0 2 lg/ml ConA 10 lg/ml ConA
0 1b 106.0c 115.0d
LIF: 500 pg/ml 2.2 97.2 114.0
LIF: 1000 pg/ml 4.0 133.0 91.0
aThis experiment was repeated for both BALB/c and CBA mice. Dif-
ferent levels of mitogen were also tested to ask if stimulation index
inﬂuenced responsiveness to exogenous LIF: all experiments showed
no eﬀect of exogenous LIF.
b813 cpm.
c86496 cpm.
d93562 cpm.
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evidence of spontaneous proliferation in axot null spleen cells
over a 7 day period (data not shown).
As a further test of functionality in the axot null spleen cells,
we measured cytokine release in response to mitogen. Both
axot null and axot heterozygous cell cultures showed a twofold
increase in IL2 following conA treatment (Fig. 3B, upper pan-
els). Thus, IL2 was not limiting for the proliferation of the
axot+/ cells. IL10 is produced by T cells, B cells and macro-
phages, and IL10 was found following both ConA and LPS
activation (Fig. 3B, lower panels). Again loss of axot resulted
in increased cytokine release relative to axot+/+ cells, this being
10-fold in both axot+/ and axot/ cells following ConA
treatment, whilst LPS-stimulation showed only a minor eﬀect
of axot gene dose. The T cell cytokines interferon gamma
(INFc) and IL4 occurred in the ConA cultures but did not
show an axot dose-related eﬀect (Fig. 3C). We concluded that
T cell cytokines are inﬂuenced by axotrophin, but this is unli-
kely to limit proliferation.
3.4. Increased LIF release from axotrophin-null T cells
In response to conA, CD4+ T lymphocytes release LIF, a
neuropoietic cytokine and growth factor belonging to the
IL6 family [13]. We found that axotrophin had a strong,
gene-dose-related suppressive eﬀect on LIF release from conA
stimulated spleen cells (Fig. 3D, left-hand panel). No LIF was
found in background controls (data not shown) nor followingFig. 4. Level of LIF release is linked to proliferation and to axot gene
dose. Measurement of LIF in 48 h culture supernatants from axot wild
type spleen cells compared to DNA synthesis (solid line), and from
axot +/+, +/, and / littermates (dashed line). The six measure-
ments (solid line) were from three diﬀerent experiments where either 2,
10, or 20 lg/ml conA had been used as mitogen. The dashed line shows
responses of spleen cells from axot littermates. Note that the axot+/+
littermate had the same relationship between DNA synthesis and LIF
release, whilst the axot+/ and axot/ cells showed a progressive
increase in LIF release relative to proliferation.LPS treatment (Fig. 3D, right-hand panel), regardless of axot
genotype.
Given the close correlation between T cell proliferation and
LIF, relative to axot dose (compare left-hand panels in Fig. 3A
and D), we asked if LIF was a limiting factor for proliferation
in the axot+/+ T cells. We ﬁrst looked for a relationship be-
tween proliferation and release of endogenous LIF in the wild
type BALB/c splenocytes by inducing diﬀerent levels of prolif-
eration and found a direct correlation (Fig. 4, solid line). To
test if this correlation was due to LIF supporting T cell prolif-
eration, we added exogenous LIF to wild type spleen cells but
found no major eﬀect on conA-induced proliferation (Table 1)
nor on cytokine release (data not shown). We therefore con-
cluded that endogenous LIF is tightly coupled to T cell prolif-
eration and that exogenous LIF is unable to override this
endogenous coupling.
3.5. Loss of axot may uncouple the link between LIF and T cell
proliferation
We next asked if the eﬀect of axotrophin on ampliﬁed LIF
release was coupled to the eﬀect of axotrophin on T cell hy-
per-proliferation. We found that lack of axot had a far greater
eﬀect on LIF (Fig. 4, dashed line). This altered relationship be-
tween proliferation and LIF, qualiﬁed by axot gene dose,
would be compatible with axotrophin playing a role in nega-
tive feedback regulation of endogenous LIF, following LIF-in-
duced signalling. STAT3 transduces signals from the LIF
receptor and this pathway is negatively regulated by SOCS3
[13]. We speculate that axotrophin may co-operate with
SOCS3 in this negative feedback: thus, in the absence of axo-Table 2
Axotrophin and LIF are speciﬁcally associated with regulatory
transplantation tolerance
Tolerant spleen Rejected spleen Tol/Rej
(fold inc.)
(i) Gene Level* Fold inc.** Level* Fold inc.**
INFc
(K00083)
64 0.69 3103 11.98 0.057
Axot
(AF155739)
416 2.9 296 1.0 2.9
Tolerant spleen Rejected spleen Tol/Rej %
(ii) Cytokine @ 123 h (pg/ml supernatant)
INFc 1859 8587 22
LIF 230 34 676
*Level of gene expression at 123 h.
**Increase in expression level between 48 and 123 h.
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revealed by the ampliﬁed release of LIF.
3.6. Both axotrophin and LIF are linked to regulatory immune
tolerance
Ex vivo comparisons of tolerance versus rejection revealed
axotrophin as one of the eight genes showing selective ampliﬁ-
cation in tolerance: in contrast, interferon gamma was very
strongly associated with rejection (Table 2(i) and reported in
detail elsewhere [7]). Release of cytokine was also measured
and here there was selective release of LIF in tolerance, whilst
interferon gamma was again associated with rejection (Table
2(ii)). The relationship between LIF and tolerance extended
to the discovery that cloned regulatory T lymphocytes release
high levels of LIF [14].
Overall, we show for the ﬁrst time that LIF and axotrophin
are functionally linked, and that both LIF and axotrophin are
linked to regulatory immune tolerance. These results have
wider implications including the relationship between axotro-
phin and LIF in the regulation of stem cells. Future studies will
analyse both axotrophin null and LIF null mice to dissect the
molecular mechanisms of this control.
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